The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10493 malaria professionals are enjoying the free benefits of MalariaWorld today

CareStart G6PD

Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania

October 1, 2019 - 14:27 -- Open Access
Oum kelthoum Mamadou Djigo, Mohamed Abdallahi Bollahi, Moina Hasni Ebou, Mohamed Salem Ould Ahmedou Salem, Rachida Tahar, Hervé Bogreau, Leonardo Basco, Ali Ould Mohamed Salem Boukhary
PLoS ONE 14(9): e0220977

Primaquine is recommended by the World Health Organization (WHO) for radical treatment of Plasmodium vivax malaria. This drug is known to provoke acute hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Due to lack of data on G6PD deficiency, the use of primaquine has been limited in Africa. In the present study, G6PD deficiency was investigated in blood donors of various ethnic groups living in Nouakchott, a P. vivax endemic area in Mauritania.

Medical Condition: 
Subscribe to RSS - CareStart G6PD